论文部分内容阅读
目的:建立精蛋白生物合成人胰岛素注射液(预混30R)的药物利用评价(DUE)标准,为合理使用该药提供参考。方法:参照国内外文献及糖尿病治疗的权威指南,结合德尔菲专家咨询法建立药物利用评价标准,经评价、干预、再评价的过程得出精蛋白生物合成人胰岛素注射液(预混30R)的最终DUE标准。结果:精蛋白生物合成人胰岛素注射液(预混30R)DUE标准包括用药指征、用药过程、用药结果三个部分,具有临床可行性。结论:DUE模式对规范临床药物的合理使用具有一定的促进作用,可为相关医疗机构开展DUE工作提供参考。
Objective: To establish the standard of drug utilization evaluation (DUE) of protamine biosynthesis human insulin injection (premixed 30R) to provide reference for rational use of this drug. Methods: According to the domestic and foreign literatures and authoritative guideline of diabetes treatment, combined with the Delphi expert consultation method, the evaluation standard of drug use was established. Through the process of evaluation, intervention and reevaluation, the protamine biosynthesis human insulin injection (premixed 30R) The final DUE standard. Results: The protamine biosynthesis human insulin injection (premixed 30R) DUE criteria include drug indications, medication process, drug results of three parts, with clinical feasibility. Conclusion: The DUE model can promote the rational use of clinical drugs and provide a reference for DUE in related medical institutions.